Vanguard €pean Stk Idx Ins Pl $ Acc |
Performance History | 31/10/2024 |
Growth of 1,000 (EUR) |
Fund | -3.1 | 25.5 | -9.2 | 16.2 | 8.3 | |
+/-Cat | -1.8 | 2.6 | 4.0 | 2.0 | 1.2 | |
+/-Idx | -0.2 | 0.1 | 0.5 | 0.3 | 0.1 | |
Category: Europe Large-Cap Blend Equity | ||||||
Benchmarks: Morningstar DM Eur TME NR EUR |
Key Stats | ||
NAV 05/11/2024 | USD 171.07 | |
Day Change | 0.07% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
ISIN | IE00BFPM9K89 | |
Fund Size (Mil) 05/11/2024 | USD 4228.94 | |
Share Class Size (Mil) 05/11/2024 | USD 72.31 | |
Max Initial Charge | - | |
Ongoing Charge 01/03/2024 | 0.08% |
Investment Objective: Vanguard €pean Stk Idx Ins Pl $ Acc |
The Fund seeks to provide long-term growth of capital by tracking the performance of the Index. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Not Disclosed 14/09/1998 | ||
Inception Date 19/12/2013 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR USD | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Vanguard €pean Stk Idx Ins Pl $ Acc | 30/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk AS Class B | Healthcare | 3.30 |
ASML Holding NV | Technology | 2.90 |
Nestle SA | Consumer Defensive | 2.30 |
AstraZeneca PLC | Healthcare | 2.10 |
SAP SE | Technology | 2.07 |
Increase Decrease New since last portfolio | ||
Vanguard €pean Stk Idx Ins Pl $ Acc |